Connect with us

Hi, what are you looking for?

Stock

C4 Therapeutics stock surges on positive early cancer trial results

Shares of C4 Therapeutics experienced a significant surge, climbing 29% in premarket trading. This rally came after the company released encouraging data from two early-stage trials of its leading cancer drug, cemsidomide.

The first trial focused on the use of cemsidomide in combination with dexamethasone for patients suffering from relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. Results showed a 36% overall response rate (ORR) at the highest dose, with a 26% ORR observed across all doses.

Additionally, a separate Phase 1 trial evaluated cemsidomide as a single-agent therapy in patients with Non-Hodgkin’s Lymphoma, a cancer affecting the lymphatic system. The findings from this study indicated a 38% ORR across the various doses tested.

Analysts have shown optimism regarding the trial outcomes. A Jefferies analyst commented on the dose-dependent response observed in the RRMM trial, suggesting that higher doses may lead to improved efficacy. The analyst expressed a belief that cemsidomide could be the best in its class within the CelMOD category, citing potential advantages in both efficacy and safety. The firm maintained a buy rating on C4 Therapeutics with a price target (PT) of $14.

Echoing this positive sentiment, a Stifel analyst highlighted the data as evidence that cemsidomide could possess a best-in-class therapeutic index. The analyst emphasized the drug’s suitability for multi-drug combination treatments in myeloma, reiterating a buy rating for the company’s stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

    Economy

    LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

    Editor's Pick

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Latest News

    Warner Bros. Discovery said Thursday its streaming platform Max added 7.2 million global subscribers in the third quarter. It marked the biggest quarterly growth for...

    Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 beneficialinvestmentnow.com